COX Nicox SA

Number of voting rights as of April 30, 2020

Number of voting rights as of April 30, 2020

Nicox SA

Société anonyme with a registered capital of € 33,469,770

Head Office:

DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis 

R.C.S. GRASSE 403.942.642

On May 4, 2020,

MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS

(Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF)

  As of April 30, 2020
Total number of shares composing the share capital 33,469,770
Total number of voting rights 33,469,770
Total number of voting rights, calculated based on the total number of shares, including the shares deprived of voting rights 33,469,770

---------------



Phone: 00

Fax : +33  4-97-24-53-99

Attachment

EN
04/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nicox SA

 PRESS RELEASE

Nicox: Second notice of the Ordinary and Extraordinary Shareholders' M...

Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent Press Release Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agentApril 24, 2024 – release at 07:30 CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, informs its shareholders that the Ordinary and Extraordinary General Meeting, having been unable to deliberate on April 10, 2024 as the quorum required by law has not been r...

 PRESS RELEASE

Nicox : Deuxième convocation à l’Assemblée Générale Ordinaire et Extra...

Nicox : Deuxième convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 6 mai 2024 et désignation d’un mandataire ad hoc Communiqué de presseNicox : Deuxième convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 6 mai 2024 et désignation d’un mandataire ad hoc24 avril 2024 – diffusion à 07h30Sophia Antipolis, FranceNicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), société internationale spécialisée en ophtalmologie, informe ses actionnaires que l’assemblée générale ordinaire et extraordinaire, n’ayant pu délibérer le 10 avril 2024 faute de réun...

 PRESS RELEASE

Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial ...

Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results Press Release Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results Nicox Group revenue of €4.4 million (net revenue1 €3.9 million) for first quarter 2024Nicox Group cash of €9.1 million on March 31, 2024 which finances the Company until at least November 2024 April 22, 2024 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided the revenue and cash position for Nicox SA and its subsid...

 PRESS RELEASE

Nicox : Point financier sur le premier trimestre 2024 et résultats fin...

Nicox : Point financier sur le premier trimestre 2024 et résultats financiers de l’année 2023 Communiqué de presseNicox : Point financier sur le premier trimestre 2024 et résultats financiers de l’année 2023 Chiffre d’affaires du Groupe de €4,4 millions (net1 de €3,9 millions) pour le premier trimestre 2024Trésorerie du Groupe au 31 mars 2024 s’élevant à €9,1 millions et horizon de trésorerie à novembre 2024 22 avril 2024 – diffusion à 07h30Sophia Antipolis, FranceNicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), société internationale spécialisée en ophtalmologie...

 PRESS RELEASE

Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting

Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting Press Release Nicox: 2024 Ordinary and Extraordinary Shareholder MeetingApril 9, 2024 – release at 17:30 CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, informs its shareholders that the Ordinary and Extraordinary general meeting convened on first call on Wednesday April 10, 2024, will not be held as the quorum required by law has not been reached.The shareholders of Nicox are thus convened on second call for an Ordinary and Extraordinary general meeting on the same...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch